News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Xichun Hu

Articles by Xichun Hu

141 DESTINY-Breast06 Post Hoc Analysis by Physician’s Choice of Chemotherapy: Efficacy and Safety of Trastuzumab Deruxtecan Versus Physician’s Choice of Chemotherapy in Hormone Receptor–Positive, HER2-Low or -Ultralow Metastatic Breast Cancer

ByCarlos H Barrios,Aditya Bardia, MD, MPH, FASCO,Xichun Hu,Rebecca Dent, MD,Kan Yonemori,Alyssa Morgan,Giuseppe Curigliano

April 30th 2026

142 Exploratory Biomarker Analysis of Trastuzumab Deruxtecan Versus Physician’s Choice of Chemotherapy in HER2-Low/Ultralow, Hormone Receptor–Positive Metastatic Breast Cancer in DESTINY-Breast06

ByRebecca Dent, MD,Giuseppe Curigliano,Xichun Hu,Kan Yonemori,Carlos H Barrios,Alyssa Morgan,Aditya Bardia, MD, MPH, FASCO

April 30th 2026

Latest Updated Articles

Trending on CancerNetwork

FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer

Combining a PCNA Inhibitor with KRAS-Targeting Agents in PDAC

Elranatamab Significantly Improves PFS in R/R Multiple Myeloma Trial

Targeting KRAS in Pancreatic Cancer: What is Daraxonrasib’s Mechanism of Action?

Tovecimig/Paclitaxel Meets PFS, Misses OS End Points in 2L Biliary Tract Cancer